WallStSmart

Bluejay Diagnostics Inc (BJDX)vsBoston Scientific Corp (BSX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

BSX leads profitability with a 17.3% profit margin vs 0.0%. BSX earns a higher WallStSmart Score of 76/100 (B+).

BJDX

Avoid

26

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 2/9Altman Z: -7.47

BSX

Strong Buy

76

out of 100

Grade: B+

Growth: 8.0Profit: 7.0Value: 5.3Quality: 6.3
Piotroski: 5/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BJDX.

BSXSignificantly Overvalued (-29.4%)

Margin of Safety

-29.4%

Fair Value

$37.35

Current Price

$48.55

$11.20 premium

UndervaluedFair: $37.35Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BJDX2 strengths · Avg: 10.0/10
Price/BookValuation
1.2x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

BSX5 strengths · Avg: 8.6/10
EPS GrowthGrowth
100.0%10/10

Earnings expanding 100.0% YoY

Market CapQuality
$70.87B9/10

Large-cap with strong market position

PEG RatioValuation
0.588/10

Growing faster than its price suggests

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.6%8/10

Strong operational efficiency at 20.6%

Areas to Watch

BJDX4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$4.49M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

BSX0 concerns · Avg: 0/10

No major concerns identified

Comparative Analysis Report

WallStSmart Research

Bull Case : BJDX

The strongest argument for BJDX centers on Price/Book, Debt/Equity.

Bull Case : BSX

The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.

Bear Case : BJDX

The primary concerns for BJDX are Revenue Growth, EPS Growth, Market Cap.

Bear Case : BSX

No major red flags identified for BSX, but monitor valuation.

Key Dynamics to Monitor

BJDX profiles as a value stock while BSX is a mature play — different risk/reward profiles.

BJDX carries more volatility with a beta of 0.72 — expect wider price swings.

BSX is growing revenue faster at 11.6% — sustainability is the question.

BSX generates stronger free cash flow (171M), providing more financial flexibility.

Bottom Line

BSX scores higher overall (76/100 vs 26/100), backed by strong 17.3% margins and 11.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Bluejay Diagnostics Inc

HEALTHCARE · MEDICAL DEVICES · USA

Bluejay Diagnostics Inc. is an innovative medical technology firm focused on advancing patient care through cutting-edge diagnostic solutions aimed at early disease detection. Leveraging a proprietary platform that combines artificial intelligence with point-of-care testing, the company enhances diagnostic accuracy and speed, providing healthcare professionals with timely and actionable insights. With a robust commitment to research and development, Bluejay is adeptly positioned to fill significant healthcare gaps and cater to the growing demand for trustworthy and innovative diagnostic tools in a rapidly changing medical landscape.

Visit Website →

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Want to dig deeper into these stocks?